Iontophoretic transdermal delivery device

Details Iontophoretic transdermal delivery device Iontophoretic transdermal delivery device

2000-06-15

2003-05-20

Nguyen, Anhtuan T. (Department: 3763)

Surgery

Means for introducing or removing material from body for...

Infrared, visible light, ultraviolet, x-ray or electrical...

C424S449000

Reexamination Certificate

active

06567693

ABSTRACT:

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not Applicable
BACKGROUND OF THE INVENTION
Transdermal administration of drugs is increasing in popularity. Most transdermal systems deliver the drug by passive diffusion using the concentration gradient as the driving force. Facilitated transdermal systems are also available and include penetration enhancers, phonophoresis and iontophoresis. Most transdermal systems use the non-ionized form of the drug with the exception of iontophoresis, which uses the ionized form. Upon application of a small electric current and the placement of the charged drug under the appropriate electrode, the drug is “repelled” away from the electrode through the skin.
There are four problems typically associated with drug delivery via iontophoresis. First, as the current is applied, electroendosmotic (EEO) flow occurs wherein water moves from the drug-containing matrix into the skin. This osmotic flow carries drug with it but also causes water to accumulate in the interface of the patch and the skin, and limits the time the patch is usable. Second, an ionized drug in aqueous solution is not as stable as one in a non-aqueous system and tends to degrade more rapidly. Most of the patch matrices currently in use include the drug in a hydrophilic “gel”, which contains a significant percentage of water. A third problem is that such gels tend to dry out with time, rendering the patch ineffective. Fourth, most iontophoretic patches last for only a few hours under active usage. In most iontophoretic transdermal delivery systems the drug is placed in a solution which is placed on a gauze pad or instilled into a special electrode-containing reservoir with a gel barrier or is incorporated into a water-based hydrogel. An iontophoretic system which employed a drug matrix which avoided most of these problems would be desirable.


REFERENCES:
patent: 4622031 (1986-11-01), Sibalis
patent: 4690683 (1987-09-01), Chien et al.
patent: 4725263 (1988-02-01), McNichols et al.
patent: 4820263 (1989-04-01), Spevak et al.
patent: 5057072 (1991-10-01), Phipps
patent: 5084008 (1992-01-01), Phipps
patent: 5087241 (1992-02-01), Mathiesen et al.
patent: 5162042 (1992-11-01), Gyory et al.
patent: 5203768 (1993-04-01), Haak et al.
patent: 5221254 (1993-06-01), Phipps
patent: 5254346 (1993-10-01), Tucker et al.
patent: 5284471 (1994-02-01), Sage, Jr.
patent: 5320731 (1994-06-01), Muller et al.
patent: 5322502 (1994-06-01), Theeuwes et al.
patent: 5334138 (1994-08-01), Sage, Jr. et al.
patent: 5374241 (1994-12-01), Lloyd et al.
patent: 5395310 (1995-03-01), Untereker et al.
patent: 5423739 (1995-06-01), Phipps et al.
patent: 5445607 (1995-08-01), Venkateshwaran et al.
patent: 5458569 (1995-10-01), Kirk, III et al.
patent: 5464387 (1995-11-01), Haak et al.
patent: 5647844 (1997-07-01), Haak et al.
patent: 5697896 (1997-12-01), McNichols et al.
patent: 5736580 (1998-04-01), Huntington et al.
patent: 5817004 (1998-10-01), Evers et al.
patent: 5840336 (1998-11-01), Hsu et al.
patent: 5882677 (1999-03-01), Kupperblatt
patent: 6119036 (2000-09-01), Allen, Jr.
patent: 0278473 (1988-08-01), None

Affiliated with

Also associated with

Rating

Iontophoretic transdermal delivery device does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Iontophoretic transdermal delivery device, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Iontophoretic transdermal delivery device will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3008142